We at the Animal Wellness Center would like to tell you about our new clinic kitty, Alani! She came to us a few months ago as a tiny kitten still requiring milk from her mother. The problem was that her siblings were stronger and kept her from accessing her mother's nipples. That's where our staff stepped in. We took the little kitten and bottle fed her for several days until the clients could take over feeding duties. Within very little time, she had grown stronger and was able to latch on by herself.
The clients decided to give us this little kitten, and now she is our new clinic cat. Her name is Alani and she is a feisty little red kitten. You can look forward to her greeting you at the Animal Wellness Center in the coming weeks.
We also would like to share with you a study done on Cannabidiol or CBD oil.
We get many questions on it, and felt this article would be helpful or useful information for you.
From this article
Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs
1Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States
2Department of Molecular Medicine, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States
3Department of Population Medicine, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States
4Proteomic and Metabolomic Facility, Colorado State University, Fort Collins, CO, United States
5Metzger Animal Hospital, State College, PA, United States
Objectives: The objectives of this study were to determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA).
Methods: Single-dose pharmacokinetics was performed using two different doses of CBD enriched (2 and 8 mg/kg) oil. Thereafter, a randomized placebo-controlled, veterinarian, and owner blinded, cross-over study was conducted. Dogs received each of two treatments: CBD oil (2 mg/kg) or placebo oil every 12 h. Each treatment lasted for 4 weeks with a 2-week washout period. Baseline veterinary assessment and owner questionnaires were completed before initiating each treatment and at weeks 2 and 4. Hematology, serum chemistry and physical examinations were performed at each visit. A mixed model analysis, analyzing the change from enrollment baseline for all other time points was utilized for all variables of interest, with a p ≤ 0.05 defined as significant.
Results: Pharmacokinetics revealed an elimination half-life of 4.2 h at both doses and no observable side effects. Clinically, canine brief pain inventory and Hudson activity scores showed a significant decrease in pain and increase in activity (p < 0.01) with CBD oil. Veterinary assessment showed decreased pain during CBD treatment (p < 0.02). No side effects were reported by owners, however, serum chemistry showed an increase in alkaline phosphatase during CBD treatment (p < 0.01).
Clinical significance: This pharmacokinetic and clinical study suggests that 2 mg/kg of CBD twice daily can help increase comfort and activity in dogs with OA.